Cancer Pain - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 5, 3, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Cancer Pain.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Pain Overview 8
Therapeutics Development 9
Pipeline Products for Cancer Pain - Overview 9
Pipeline Products for Cancer Pain - Comparative Analysis 10
Cancer Pain - Therapeutics under Development by Companies 11
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13
Cancer Pain - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Cancer Pain - Products under Development by Companies 18
Cancer Pain - Products under Investigation by Universities/Institutes 21
Cancer Pain - Companies Involved in Therapeutics Development 22
Alexza Pharmaceuticals Inc 22
AngioChem Inc 23
Aoxing Pharmaceutical Company Inc 24
Aphios Corp 25
AstraZeneca Plc 26
Benitec Biopharma Ltd 27
BioDelivery Sciences International Inc 28
ChironWells GmbH 29
Colby Pharmaceutical Company 30
Daiichi Sankyo Company Ltd 31
Dompe Farmaceutici SpA 32
Fujimoto Pharmaceutical Corp 33
Grunenthal GmbH 34
GW Pharmaceuticals Plc 35
Hisamitsu Pharmaceutical Co Inc 36
Immupharma Plc 37
IntelGenx Corp 38
iX Biopharma Ltd 39
Kancera AB 40
Klaria Pharma Holding AB 41
Komipharm International Co Ltd 42
KPI Therapeutics Inc 43
Neurocentrx Pharma Ltd 44
Nippon Kayaku Co Ltd 45
Orion Oyj 46
Pain Therapeutics Inc 47
Pfizer Inc 48
Pharmaleads SA 49
Recordati SpA 50
Ribomic Inc. 51
Trillium Therapeutics Inc 52
Virobay Inc 53
WEX Pharmaceuticals Inc 54
Zynerba Pharmaceuticals Inc 55
Cancer Pain - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
ANG-2002 - Drug Profile 67
AQU-118 - Drug Profile 68
AZD-8797 - Drug Profile 69
BBI-11008 - Drug Profile 71
buprenorphine hydrochloride - Drug Profile 72
cebranopadol - Drug Profile 73
CPC-111 - Drug Profile 76
crotalphine - Drug Profile 77
CSTI-200 - Drug Profile 78
dexmedetomidine hydrochloride - Drug Profile 79
dronabinol - Drug Profile 81
Drug 1 for Migraine and Cancer Pain - Drug Profile 82
Drug 2 for Migraine and Cancer Pain - Drug Profile 83
Drug 3 for Migraine and Cancer Pain - Drug Profile 84
Drug for Cancer Neuropathic Pain - Drug Profile 85
Drug for Migraine and Cancer Pain - Drug Profile 86
fentanyl - Drug Profile 87
fentanyl citrate - Drug Profile 88
fentanyl citrate - Drug Profile 90
fentanyl citrate - Drug Profile 91
fentanyl citrate ER - Drug Profile 92
gabapentin - Drug Profile 93
HP-3150 - Drug Profile 94
HS-198 - Drug Profile 95
hydromorphone hydrochloride - Drug Profile 96
HYLP-002 - Drug Profile 97
INT-0010 - Drug Profile 98
IPP-102199 - Drug Profile 99
methadone hydrochloride - Drug Profile 100
nabiximols - Drug Profile 101
Nervarna - Drug Profile 108
PAX-1 - Drug Profile 109
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile 110
Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 111
PL-265 - Drug Profile 112
QX-314 - Drug Profile 113
RBM-004 - Drug Profile 114
RBM-007 - Drug Profile 115
resiniferatoxin - Drug Profile 116
saracatinib difumarate - Drug Profile 118
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 122
Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 123
tanezumab - Drug Profile 124
Tetrodotoxin - Drug Profile 127
tilidine hydrochloride - Drug Profile 129
U-2902 - Drug Profile 130
VBY-825 - Drug Profile 132
zucapsaicin - Drug Profile 133
ZYN-001 - Drug Profile 135
Cancer Pain - Dormant Projects 137
Cancer Pain - Discontinued Products 141
Cancer Pain - Product Development Milestones 142
Featured News & Press Releases 142
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 152
Disclaimer 153

List of Tables

Number of Products under Development for Cancer Pain, H2 2016 13
Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Comparative Analysis by Late Stage Development, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 19
Comparative Analysis by Early Stage Development, H2 2016 20
Comparative Analysis by Unknown Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2016 25
Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2016 26
Cancer Pain - Pipeline by AngioChem Inc, H2 2016 27
Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 28
Cancer Pain - Pipeline by Aphios Corp, H2 2016 29
Cancer Pain - Pipeline by AstraZeneca Plc, H2 2016 30
Cancer Pain - Pipeline by Benitec Biopharma Ltd, H2 2016 31
Cancer Pain - Pipeline by BioDelivery Sciences International Inc, H2 2016 32
Cancer Pain - Pipeline by ChironWells GmbH, H2 2016 33
Cancer Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 34
Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 35
Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016 36
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2016 37
Cancer Pain - Pipeline by Grunenthal GmbH, H2 2016 38
Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 39
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 40
Cancer Pain - Pipeline by Immupharma Plc, H2 2016 41
Cancer Pain - Pipeline by IntelGenx Corp, H2 2016 42
Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2016 43
Cancer Pain - Pipeline by Kancera AB, H2 2016 44
Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2016 45
Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2016 46
Cancer Pain - Pipeline by KPI Therapeutics Inc, H2 2016 47
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016 48
Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2016 49
Cancer Pain - Pipeline by Orion Oyj, H2 2016 50
Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2016 51
Cancer Pain - Pipeline by Pfizer Inc, H2 2016 52
Cancer Pain - Pipeline by Pharmaleads SA, H2 2016 53
Cancer Pain - Pipeline by Recordati SpA, H2 2016 54
Cancer Pain - Pipeline by Ribomic Inc., H2 2016 55
Cancer Pain - Pipeline by Trillium Therapeutics Inc, H2 2016 56
Cancer Pain - Pipeline by Virobay Inc, H2 2016 57
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2016 58
Cancer Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 59
Assessment by Monotherapy Products, H2 2016 60
Number of Products by Stage and Target, H2 2016 62
Number of Products by Stage and Mechanism of Action, H2 2016 65
Number of Products by Stage and Route of Administration, H2 2016 68
Number of Products by Stage and Molecule Type, H2 2016 70
Cancer Pain - Dormant Projects, H2 2016 141
Cancer Pain - Dormant Projects (Contd..1), H2 2016 142
Cancer Pain - Dormant Projects (Contd..2), H2 2016 143
Cancer Pain - Dormant Projects (Contd..3), H2 2016 144
Cancer Pain - Discontinued Products, H2 2016 145